###begin article-title 0
The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders
###end article-title 0
###begin p 1
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 783 791 <span type="species:ncbi:9606">patients</span>
###xml 873 880 <span type="species:ncbi:9606">patient</span>
Recent evidence suggests that the GABA transporter 1 (GAT-1; SLC6A1) plays a role in the pathophysiology and treatment of anxiety disorders. In order to understand the impact of genetic variation within SLC6A1 on pathological anxiety, we performed a case-control association study with anxiety disorder patients with and without syndromal panic attacks. Using the method of sequential addition of cases, we found that polymorphisms in the 5' flanking region of SLC6A1 are highly associated with anxiety disorders when considering the severity of syndromal panic attacks as phenotype covariate. Analysing the effect size of the association, we observed a constant increase in the odds ratio for disease susceptibility with an increase in panic severity (OR ~ 2.5 in severely affected patients). Nominally significant association effects were observed considering the entire patient sample. These data indicate a high load of genetic variance within SLC6A1 on pathological anxiety and highlight GAT-1 as a promising target for treatment of anxiety disorders with panic symptoms.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00702-008-0075-y) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2004</xref>
###xml 177 182 177 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2005a</xref>
###xml 291 296 291 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2005b</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2001</xref>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2003</xref>
Anxiety disorders are frequent psychiatric conditions in the general population with lifetime prevalence rates ranging from 13.6 up to 28.8% (Alonso et al. 2004; Kessler et al. 2005a). Due to high comorbidity rates with other psychiatric disorders and physical illness (e.g., Kessler et al. 2005b; Mayer et al. 2001; Merikangas et al. 2003) quality of life is seriously compromised and social disadvantage often arises resulting in impairment comparable to chronic somatic disorders.
###end p 6
###begin p 7
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1995</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2008</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2007</xref>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2005</xref>
A great number of studies have been carried out investigating the influence of genetic and environmental underpinnings of pathological anxiety. So far, epidemiological evidence suggests a familial aggregation of anxiety disorders (e.g., Horwath et al. 1995; Low et al. 2008; Nocon et al. 2007) which is highly attributable to genetic factors with heritability estimates around 30% (e.g., Hettema et al. 2005). The understanding of the genetic mechanisms that contribute to development or maintenance of anxiety disorders may offer new insights in the pathophysiology of these disorders and potentially novel therapeutic strategies.
###end p 7
###begin p 8
###xml 285 286 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 418 427 414 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1996&#8211;1997</xref>
###xml 519 520 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 677 681 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2007</xref>
###xml 692 696 688 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2003</xref>
###xml 752 753 748 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 968 972 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">2004</xref>
###xml 997 1001 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">2005</xref>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
Several lines of preclinical and clinical evidence support the view that the gamma-aminobutyric acid (GABA) system is a major candidate in the pathogenesis of anxiety, fear and related psychopathological conditions. It has been shown that pentylenetetrazole, an agent antagonizing GABAA receptor function, induces symptoms of anxiety, flash backs of traumatic memories and strong avoidance behaviour (Kalueff and Nutt 1996-1997). Conversely, augmentation of brain GABA function by positive allosteric modulators of GABAA receptors, e.g., using benzodiazepines, promotes rapid and profound anxiolysis in patients suffering from affective and anxiety disorders (Kalueff and Nutt 2007; Nemeroff 2003). Apart from pharmacological agents modulating the GABAA receptor, a novel class of drugs (initially developed as antiepileptic medication) targeting synaptic transport or metabolism of GABA has emerged in the clinical management of anxiety states (Rogawski and Loescher 2004; Zwanzger and Rupprecht 2005).
###end p 8
###begin p 9
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2003</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2003</xref>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2004</xref>
###xml 919 923 919 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2006</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2006</xref>
###xml 960 964 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2005</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2003</xref>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">2007</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">2001</xref>
###xml 945 952 <span type="species:ncbi:185739">Pollack</span>
Among them, drugs have been developed that act by blockade of GABA transporters (GAT), thereby inhibiting GABA uptake from the synaptic cleft. Four subtypes of GATs, GAT-1, GAT-2, GAT-3 and Betaine/GABA transporter 1 (BGT-1) have been identified. GAT-1 constitutes the main neuronal transporter isoform that is abundantly expressed on presynaptic GABAergic terminals of neurons and on glial cells (Dalby 2003; Sarup et al. 2003). The first (and only) selective inhibitor of GAT-1 sites in clinical use is tiagabine. It has been approved for add-on therapy of partial-onset seizures in adults (LaRoche and Helmers 2004). In addition, several preliminary studies report that tiagabine is effective in psychiatric diseases such as panic disorder, generalized anxiety disorder, posttraumatic stress disorder, in which augmentation of brain GABA neurotransmission is thought to alleviate clinical symptoms (Carpenter et al. 2006; Connor et al. 2006; Pollack et al. 2005; Rosenthal 2003; Sheehan et al. 2007; Zwanzger et al. 2001).
###end p 9
###begin p 10
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2001</xref>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2007</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2008</xref>
###xml 654 659 654 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2004a</xref>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 518 525 <span type="species:ncbi:185739">Pollack</span>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
In addition to the clinical benefits and relevance observed by psychotropic GAT-1 blockade in anxiety disorder patients, neurobiological evidence for aberrant GABAergic neuroinhibitory processes on the level of GABA release and reuptake comes from neuroimaging studies. Using magnetic resonance spectroscopy technique, lower levels of GABA in cortical areas and the basal ganglia of panic disorder patients (Goddard et al. 2001; Ham et al. 2007) and in the thalamus of patients suffering from social anxiety disorder (Pollack et al. 2008) as compared to healthy control subjects have been documented. In a preliminary follow-up analysis, Goddard et al. (2004a) report that the low cortical GABA levels in panic disorder patients is largely determined by familial and, possibly, genetic factors.
###end p 10
###begin p 11
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
As a consequence, the SLC6A1 gene, which encodes the GAT-1 protein, can be considered an obvious candidate gene for human gene association studies investigating the genetic liability to anxiety disorders. In the present study, we performed a case-control association study investigating the genetic variance in SLC6A1 in anxiety disorder patients with syndromal panic attacks and matched control subjects. We focused on this phenotype due to the high frequency of panic attacks in anxiety disorder patients and good clinical response to drugs that enhance GABAergic neurotransmission.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Study population
###end title 13
###begin p 14
The present study was approved by the local ethics committee. Written informed consent was obtained from all participating subjects.
###end p 14
###begin p 15
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 575 579 575 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">1997</xref>
###xml 815 822 815 822 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 822 886 822 886 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">Demographic and clinical characteristics of the study population</p>
###xml 822 886 822 886 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">Demographic and clinical characteristics of the study population</p></caption>
###xml 886 886 886 886 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 886 894 886 894 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patients</th>
###xml 894 902 894 902 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls</th>
###xml 886 902 886 902 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Patients</th><th align="left">Controls</th></tr>
###xml 886 902 886 902 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Patients</th><th align="left">Controls</th></tr></thead>
###xml 908 909 908 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 902 915 902 915 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Total <italic>N</italic> = 505</td>
###xml 902 915 902 915 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="3">Total <italic>N</italic> = 505</td></tr>
###xml 915 916 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 915 916 915 916 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>N</italic></td>
###xml 916 927 916 927 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">238 (47.1%)</td>
###xml 927 937 927 937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">267 (52.9)</td>
###xml 915 937 915 937 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>N</italic></td><td align="left">238 (47.1%)</td><td align="left">267 (52.9)</td></tr>
###xml 937 940 937 940 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Sex</td>
###xml 937 940 937 940 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="3">Sex</td></tr>
###xml 940 949 940 949 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"> Male (%)</td>
###xml 949 953 949 953 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">37.8</td>
###xml 953 957 953 957 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">39.2</td>
###xml 940 957 940 957 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"> Male (%)</td><td align="left">37.8</td><td align="left">39.2</td></tr>
###xml 957 968 957 968 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"> Female (%)</td>
###xml 968 972 968 972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">62.2</td>
###xml 972 976 972 976 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60.7</td>
###xml 957 976 957 976 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"> Female (%)</td><td align="left">62.2</td><td align="left">60.7</td></tr>
###xml 976 992 976 992 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (SD) (years)</td>
###xml 992 1003 992 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">38.2 (11.6)</td>
###xml 1003 1014 1003 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">38.5 (11.6)</td>
###xml 976 1014 976 1014 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age (SD) (years)</td><td align="left">38.2 (11.6)</td><td align="left">38.5 (11.6)</td></tr>
###xml 1014 1039 1014 1039 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age of onset (SD) (years)</td>
###xml 1039 1050 1039 1050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27.4 (11.2)</td>
###xml 1050 1050 1050 1050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1014 1050 1014 1050 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age of onset (SD) (years)</td><td align="left">27.4 (11.2)</td><td align="left"/></tr>
###xml 1050 1064 1050 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PAS total (SD)</td>
###xml 1064 1074 1064 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">29.8 (9.8)</td>
###xml 1074 1074 1074 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1050 1074 1050 1074 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PAS total (SD)</td><td align="left">29.8 (9.8)</td><td align="left"/></tr>
###xml 1074 1092 1074 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Panic attacks (SD)</td>
###xml 1092 1101 1092 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6.5 (3.1)</td>
###xml 1101 1101 1101 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1074 1101 1074 1101 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Panic attacks (SD)</td><td align="left">6.5 (3.1)</td><td align="left"/></tr>
###xml 1101 1117 1101 1117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Agoraphobia (SD)</td>
###xml 1117 1126 1117 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6.8 (3.1)</td>
###xml 1126 1126 1126 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1101 1126 1101 1126 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Agoraphobia (SD)</td><td align="left">6.8 (3.1)</td><td align="left"/></tr>
###xml 1126 1151 1126 1151 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anticipatory anxiety (SD)</td>
###xml 1151 1160 1151 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5.8 (1.7)</td>
###xml 1160 1160 1160 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1126 1160 1126 1160 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Anticipatory anxiety (SD)</td><td align="left">5.8 (1.7)</td><td align="left"/></tr>
###xml 1160 1175 1160 1175 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Disability (SD)</td>
###xml 1175 1184 1175 1184 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6.1 (2.8)</td>
###xml 1184 1184 1184 1184 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1160 1184 1160 1184 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Disability (SD)</td><td align="left">6.1 (2.8)</td><td align="left"/></tr>
###xml 1184 1204 1184 1204 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Health concerns (SD)</td>
###xml 1204 1213 1204 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.4 (2.5)</td>
###xml 1213 1213 1213 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1184 1213 1184 1213 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Health concerns (SD)</td><td align="left">4.4 (2.5)</td><td align="left"/></tr>
###xml 902 1213 902 1213 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="3">Total <italic>N</italic> = 505</td></tr><tr><td align="left"><italic>N</italic></td><td align="left">238 (47.1%)</td><td align="left">267 (52.9)</td></tr><tr><td align="left" colspan="3">Sex</td></tr><tr><td align="left"> Male (%)</td><td align="left">37.8</td><td align="left">39.2</td></tr><tr><td align="left"> Female (%)</td><td align="left">62.2</td><td align="left">60.7</td></tr><tr><td align="left">Age (SD) (years)</td><td align="left">38.2 (11.6)</td><td align="left">38.5 (11.6)</td></tr><tr><td align="left">Age of onset (SD) (years)</td><td align="left">27.4 (11.2)</td><td align="left"/></tr><tr><td align="left">PAS total (SD)</td><td align="left">29.8 (9.8)</td><td align="left"/></tr><tr><td align="left">Panic attacks (SD)</td><td align="left">6.5 (3.1)</td><td align="left"/></tr><tr><td align="left">Agoraphobia (SD)</td><td align="left">6.8 (3.1)</td><td align="left"/></tr><tr><td align="left">Anticipatory anxiety (SD)</td><td align="left">5.8 (1.7)</td><td align="left"/></tr><tr><td align="left">Disability (SD)</td><td align="left">6.1 (2.8)</td><td align="left"/></tr><tr><td align="left">Health concerns (SD)</td><td align="left">4.4 (2.5)</td><td align="left"/></tr></tbody>
###xml 886 1213 886 1213 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Patients</th><th align="left">Controls</th></tr></thead><tbody><tr><td align="left" colspan="3">Total <italic>N</italic> = 505</td></tr><tr><td align="left"><italic>N</italic></td><td align="left">238 (47.1%)</td><td align="left">267 (52.9)</td></tr><tr><td align="left" colspan="3">Sex</td></tr><tr><td align="left"> Male (%)</td><td align="left">37.8</td><td align="left">39.2</td></tr><tr><td align="left"> Female (%)</td><td align="left">62.2</td><td align="left">60.7</td></tr><tr><td align="left">Age (SD) (years)</td><td align="left">38.2 (11.6)</td><td align="left">38.5 (11.6)</td></tr><tr><td align="left">Age of onset (SD) (years)</td><td align="left">27.4 (11.2)</td><td align="left"/></tr><tr><td align="left">PAS total (SD)</td><td align="left">29.8 (9.8)</td><td align="left"/></tr><tr><td align="left">Panic attacks (SD)</td><td align="left">6.5 (3.1)</td><td align="left"/></tr><tr><td align="left">Agoraphobia (SD)</td><td align="left">6.8 (3.1)</td><td align="left"/></tr><tr><td align="left">Anticipatory anxiety (SD)</td><td align="left">5.8 (1.7)</td><td align="left"/></tr><tr><td align="left">Disability (SD)</td><td align="left">6.1 (2.8)</td><td align="left"/></tr><tr><td align="left">Health concerns (SD)</td><td align="left">4.4 (2.5)</td><td align="left"/></tr></tbody></table>
###xml 1597 1599 1597 1599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SD</italic>
###xml 1213 1618 1213 1618 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Quantitative analysis of severity of panic and anxiety symptoms using the panic and agoraphobia scale. Data are shown as the mean of the total panic and agoraphobia scale (PAS) score, the mean severity of panic attacks, phobic avoidance (agoraphobia), anticipatory anxiety, impairment of social relationships and work (disability) and assumption of somatic disease (health concerns). <italic>SD</italic> standard deviation</p>
###xml 1213 1618 1213 1618 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Quantitative analysis of severity of panic and anxiety symptoms using the panic and agoraphobia scale. Data are shown as the mean of the total panic and agoraphobia scale (PAS) score, the mean severity of panic attacks, phobic avoidance (agoraphobia), anticipatory anxiety, impairment of social relationships and work (disability) and assumption of somatic disease (health concerns). <italic>SD</italic> standard deviation</p></table-wrap-foot>
###xml 815 1618 815 1618 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="16">Demographic and clinical characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Patients</th><th align="left">Controls</th></tr></thead><tbody><tr><td align="left" colspan="3">Total <italic>N</italic> = 505</td></tr><tr><td align="left"><italic>N</italic></td><td align="left">238 (47.1%)</td><td align="left">267 (52.9)</td></tr><tr><td align="left" colspan="3">Sex</td></tr><tr><td align="left"> Male (%)</td><td align="left">37.8</td><td align="left">39.2</td></tr><tr><td align="left"> Female (%)</td><td align="left">62.2</td><td align="left">60.7</td></tr><tr><td align="left">Age (SD) (years)</td><td align="left">38.2 (11.6)</td><td align="left">38.5 (11.6)</td></tr><tr><td align="left">Age of onset (SD) (years)</td><td align="left">27.4 (11.2)</td><td align="left"/></tr><tr><td align="left">PAS total (SD)</td><td align="left">29.8 (9.8)</td><td align="left"/></tr><tr><td align="left">Panic attacks (SD)</td><td align="left">6.5 (3.1)</td><td align="left"/></tr><tr><td align="left">Agoraphobia (SD)</td><td align="left">6.8 (3.1)</td><td align="left"/></tr><tr><td align="left">Anticipatory anxiety (SD)</td><td align="left">5.8 (1.7)</td><td align="left"/></tr><tr><td align="left">Disability (SD)</td><td align="left">6.1 (2.8)</td><td align="left"/></tr><tr><td align="left">Health concerns (SD)</td><td align="left">4.4 (2.5)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p textid="17">Quantitative analysis of severity of panic and anxiety symptoms using the panic and agoraphobia scale. Data are shown as the mean of the total panic and agoraphobia scale (PAS) score, the mean severity of panic attacks, phobic avoidance (agoraphobia), anticipatory anxiety, impairment of social relationships and work (disability) and assumption of somatic disease (health concerns). <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">Patients</span>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
The study included 238 adult patients consecutively recruited from the Anxiety Disorders Outpatient Clinic of the Max Planck Institute of Psychiatry in Munich presenting with the following anxiety disorders: panic disorder with agoraphobia (71.4%), panic disorder without agoraphobia (13.0%), agoraphobia (1.7%), social phobia (7.6%), specific phobia (3.8%) and generalized anxiety disorder (2.5%). Demographic and clinical data are shown in Table 1. Patients were diagnosed by trained psychiatrists using the structured clinical interview (SCID) for DSM-IV (Wittchen et al. 1997). All patients underwent a thorough medical examination including EEG, ECG and detailed hormone laboratory assessment. Anxiety disorders due to a medical or neurological condition or a comorbid Axis II disorder were exclusion criteria.Table 1Demographic and clinical characteristics of the study populationPatientsControlsTotal N = 505N238 (47.1%)267 (52.9)Sex Male (%)37.839.2 Female (%)62.260.7Age (SD) (years)38.2 (11.6)38.5 (11.6)Age of onset (SD) (years)27.4 (11.2)PAS total (SD)29.8 (9.8)Panic attacks (SD)6.5 (3.1)Agoraphobia (SD)6.8 (3.1)Anticipatory anxiety (SD)5.8 (1.7)Disability (SD)6.1 (2.8)Health concerns (SD)4.4 (2.5)Quantitative analysis of severity of panic and anxiety symptoms using the panic and agoraphobia scale. Data are shown as the mean of the total panic and agoraphobia scale (PAS) score, the mean severity of panic attacks, phobic avoidance (agoraphobia), anticipatory anxiety, impairment of social relationships and work (disability) and assumption of somatic disease (health concerns). SD standard deviation
###end p 15
###begin p 16
Demographic and clinical characteristics of the study population
###end p 16
###begin p 17
###xml 384 386 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SD</italic>
Quantitative analysis of severity of panic and anxiety symptoms using the panic and agoraphobia scale. Data are shown as the mean of the total panic and agoraphobia scale (PAS) score, the mean severity of panic attacks, phobic avoidance (agoraphobia), anticipatory anxiety, impairment of social relationships and work (disability) and assumption of somatic disease (health concerns). SD standard deviation
###end p 17
###begin p 18
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">Patients</span>
Ethnicity was recorded using a self-reported questionnaire asking for nationality, language and ethnicity of the subject, his/her parents and grandparents. All included patients were Caucasians with 83% being of German and 17% of other European origin. Patients with Turkish, Oriental Asiatic and African origin were excluded from the analysis.
###end p 18
###begin p 19
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">1994</xref>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">1997</xref>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
A total of 267 healthy control subjects matched for ethnicity (using the same questionnaire as for patients), gender and age were recruited at the Max Planck Institute of Psychiatry (Table 1). They were randomly selected from a Munich-based community sample and screened for the presence of mood disorder, anxiety disorders including OCD and PTSD, somatoform disorder, alcohol dependence, drug abuse, psychotic disorder, dissociative disorder NOS and eating disorder using a standardized diagnostic interview (DSM-IV M-CIDI) (Wittchen 1994; Wittchen and Pfister 1997). Only individuals with a negative life-time history for these disorders were enrolled in the study.
###end p 19
###begin title 20
Assessment of dimensional measures of panic and anxiety
###end title 20
###begin p 21
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">1995</xref>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
We used the panic and agoraphobia scale (PAS) (Bandelow 1995) to assess the severity of the worst period of anxiety and panic symptoms and to further investigate associations with genetic polymorphisms in the GAT-1 gene. The total score on this scale revealed a moderate to high severity of panic and agoraphobia [mean score physician rating (SD): 29.8 (9.8)]. The sub-scores of PAS regarding the severity of panic attacks, phobic avoidance, anticipatory anxiety, impairment of social relationships and work as well as assumption of somatic disease are presented in Table 1. Ratings were performed by trained psychiatrists.
###end p 21
###begin p 22
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1959</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1960</xref>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
Psychopathological phenotyping of patients with the Hamilton Anxiety Scale revealed a mean score of 24.7 (SD 9.8), and the mean Hamilton Depression Scale score was 13.7 (SD 6.6) indicating moderate anxiety and low depression in these patients (Hamilton 1959, 1960).
###end p 22
###begin title 23
DNA preparation, SNP selection and genotyping
###end title 23
###begin p 24
On enrolment in the study, up to 40 ml of EDTA blood was drawn from each subject and DNA was extracted using a standardized procedure (Puregene whole blood DNA-extraction kit; Gentra Systems Inc., USA).
###end p 24
###begin p 25
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1165 1166 1165 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1252 1258 1252 1258 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1299 1300 1299 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1358 1369 1358 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper graph</italic>
###xml 1372 1394 1372 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lower triangular graph</italic>
###xml 1258 1505 1258 1505 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Illustration and mapping of case&#8211;control <italic>P</italic> values (nominal) for genotyped SNPs at the SLC6A1 locus (<italic>upper graph</italic>). <italic>Lower triangular graph</italic> illustrates linkage disequilibrium (LD) and block structure within the GAT-1 gene using D&#8242; as a measure for LD</p>
###xml 1258 1505 1258 1505 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Illustration and mapping of case&#8211;control <italic>P</italic> values (nominal) for genotyped SNPs at the SLC6A1 locus (<italic>upper graph</italic>). <italic>Lower triangular graph</italic> illustrates linkage disequilibrium (LD) and block structure within the GAT-1 gene using D&#8242; as a measure for LD</p></caption>
###xml 1505 1505 1505 1505 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2008_75_Fig1_HTML" id="MO1"/>
###xml 1252 1505 1252 1505 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="26">Illustration and mapping of case&#8211;control <italic>P</italic> values (nominal) for genotyped SNPs at the SLC6A1 locus (<italic>upper graph</italic>). <italic>Lower triangular graph</italic> illustrates linkage disequilibrium (LD) and block structure within the GAT-1 gene using D&#8242; as a measure for LD</p></caption><graphic position="anchor" xlink:href="702_2008_75_Fig1_HTML" id="MO1"/></fig>
###xml 68 73 <span type="species:ncbi:9606">Human</span>
For the present study, SNPs were selected from the Illumina Sentrix Human-1 Genotyping 300K BeadChip system (Illumina Inc., San Diego, USA) and mapped to the coding region and in the flanking sequence [n = 20; 15 kb up- and downstream; from position 10997825 to 11055168 (hg18)] of the GAT-1 gene [SLC6A1 (NM_003042)] on chromosome 3p25.3 (Fig. 1). SNP genotyping of a total number of 20 SNPs (average inter-polymorphism distance 3.2 kb) was performed at the Center for Applied GenoTyping, CAGT, at the Max Planck Institute of Psychiatry, Munich, Germany, using the Illumina InfiniumII technology and the protocols provided by the manufacturer. Genotype calling was according to the manufacturer's instructions. Cluster files for all SNPs were inspected by eye, and all intensities clustered well into the three canonical groups. The call rate for each SNP was >99.6% (mean 99.9%), and minor allele frequencies exceeded 6%. The reproduction error rate was below 0.0003% as judged from repeated genotyping of five samples. Genotype datasets were checked for identical samples and relatedness (no identical samples were found). No SNP showed a significant deviation (P < 0.05) from Hardy-Weinberg equilibrium (Electronic supplementary material, Table 3).Fig. 1Illustration and mapping of case-control P values (nominal) for genotyped SNPs at the SLC6A1 locus (upper graph). Lower triangular graph illustrates linkage disequilibrium (LD) and block structure within the GAT-1 gene using D' as a measure for LD
###end p 25
###begin p 26
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 100 111 100 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper graph</italic>
###xml 114 136 114 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lower triangular graph</italic>
Illustration and mapping of case-control P values (nominal) for genotyped SNPs at the SLC6A1 locus (upper graph). Lower triangular graph illustrates linkage disequilibrium (LD) and block structure within the GAT-1 gene using D' as a measure for LD
###end p 26
###begin title 27
Data analysis and statistics
###end title 27
###begin p 28
###xml 211 212 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 423 424 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 455 459 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">1993</xref>
All statistical analyses were performed using the WG-Permer software, a tool for rapid analysis of large scale genome association studies (). The association analysis for SNPs and phenotypes was conducted by chi2 tests applying an allelic model. This approach corresponds to the Armitage test of trend. As the individual tests are correlated, we used 100.000 permutations to adjust for multiple testing, namely the minimum P method of Westfall and Young (1993).
###end p 28
###begin p 29
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">1932</xref>
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2004</xref>
Second, we carried out the Fisher product method for combining tests (Fisher 1932) to get overall significance levels for the whole set of polymorphisms within the candidate region. Again, the significance of combined tests was evaluated using permutation (Binder et al. 2004).
###end p 29
###begin p 30
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2002</xref>
For the analysis of linkage disequilibrium (LD) and haplotype block delineation we used haplotypes estimated by HAPLOVIEW 4.0 (). Blocks were defined using the confidence interval method described by Gabriel et al. (2002).
###end p 30
###begin p 31
The level of significance for all statistical analyses was set to 5%.
###end p 31
###begin title 32
Results
###end title 32
###begin p 33
###xml 139 146 139 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">Methods</xref>
A total number of 20 SNPs were genotyped within the SLC6A1 locus and flanking regions with all polymorphisms passing quality control (see "Methods"), and they were thus included in the statistical analysis.
###end p 33
###begin p 34
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2004</xref>
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1999</xref>
###xml 274 277 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 277 278 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 368 371 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 371 372 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 381 387 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#955;</italic>
To test for the effects of population stratification, we applied the method of genomic controls (Binder et al. 2004; Devlin and Roeder 1999) for the data obtained from the Illumina 300K chip. Thereby, we calculated the allelic deviation between cases and controls using the chi2 statistics and compared the distribution of the obtained with the theoretically expected chi2 values. lambda, the ratio of the median of the test statistics and the median of the theoretical distribution was 1.025 indicating almost no population stratification between our study samples.
###end p 34
###begin title 35
Case-control analysis
###end title 35
###begin p 36
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 374 376 374 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 631 633 631 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 653 655 653 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 674 676 674 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1064 1071 1064 1071 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1071 1146 1071 1146 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Association of GAT-1 single nucleotide polymorphisms with anxiety disorders</p>
###xml 1071 1146 1071 1146 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Association of GAT-1 single nucleotide polymorphisms with anxiety disorders</p></caption>
###xml 1146 1150 1146 1150 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SNPs</th>
###xml 1150 1158 1150 1158 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patients</th>
###xml 1158 1166 1158 1166 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls</th>
###xml 1166 1167 1166 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1166 1173 1166 1173 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic> value</th>
###xml 1146 1173 1146 1173 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">SNPs</th><th align="left">Patients</th><th align="left">Controls</th><th align="left"><italic>P</italic> value</th></tr>
###xml 1146 1173 1146 1173 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">SNPs</th><th align="left">Patients</th><th align="left">Controls</th><th align="left"><italic>P</italic> value</th></tr></thead>
###xml 1173 1182 1173 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2930152</td>
###xml 1182 1210 1182 1210 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA, 18.1; AG, 50.4; GG, 31.5</td>
###xml 1210 1238 1210 1238 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA, 13.9; AG, 43.8; GG, 48.7</td>
###xml 1238 1244 1238 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0147</td>
###xml 1173 1244 1173 1244 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2930152</td><td align="left">AA, 18.1; AG, 50.4; GG, 31.5</td><td align="left">AA, 13.9; AG, 43.8; GG, 48.7</td><td char="." align="char">0.0147</td></tr>
###xml 1244 1253 1244 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2697153</td>
###xml 1253 1281 1253 1281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA, 35.7; AG, 48.3; GG, 16.0</td>
###xml 1281 1309 1281 1309 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA, 46.8; AG, 40.4; GG, 12.8</td>
###xml 1309 1315 1309 1315 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0181</td>
###xml 1244 1315 1244 1315 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2697153</td><td align="left">AA, 35.7; AG, 48.3; GG, 16.0</td><td align="left">AA, 46.8; AG, 40.4; GG, 12.8</td><td char="." align="char">0.0181</td></tr>
###xml 1315 1323 1315 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs956053</td>
###xml 1323 1350 1323 1350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CC, 54.6; CT, 41.2; TT, 4.2</td>
###xml 1350 1378 1350 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CC, 50.6; CT, 36.7; TT, 12.7</td>
###xml 1378 1384 1378 1384 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0263</td>
###xml 1315 1384 1315 1384 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs956053</td><td align="left">CC, 54.6; CT, 41.2; TT, 4.2</td><td align="left">CC, 50.6; CT, 36.7; TT, 12.7</td><td char="." align="char">0.0263</td></tr>
###xml 1173 1384 1173 1384 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">rs2930152</td><td align="left">AA, 18.1; AG, 50.4; GG, 31.5</td><td align="left">AA, 13.9; AG, 43.8; GG, 48.7</td><td char="." align="char">0.0147</td></tr><tr><td align="left">rs2697153</td><td align="left">AA, 35.7; AG, 48.3; GG, 16.0</td><td align="left">AA, 46.8; AG, 40.4; GG, 12.8</td><td char="." align="char">0.0181</td></tr><tr><td align="left">rs956053</td><td align="left">CC, 54.6; CT, 41.2; TT, 4.2</td><td align="left">CC, 50.6; CT, 36.7; TT, 12.7</td><td char="." align="char">0.0263</td></tr></tbody>
###xml 1146 1384 1146 1384 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">SNPs</th><th align="left">Patients</th><th align="left">Controls</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">rs2930152</td><td align="left">AA, 18.1; AG, 50.4; GG, 31.5</td><td align="left">AA, 13.9; AG, 43.8; GG, 48.7</td><td char="." align="char">0.0147</td></tr><tr><td align="left">rs2697153</td><td align="left">AA, 35.7; AG, 48.3; GG, 16.0</td><td align="left">AA, 46.8; AG, 40.4; GG, 12.8</td><td char="." align="char">0.0181</td></tr><tr><td align="left">rs956053</td><td align="left">CC, 54.6; CT, 41.2; TT, 4.2</td><td align="left">CC, 50.6; CT, 36.7; TT, 12.7</td><td char="." align="char">0.0263</td></tr></tbody></table>
###xml 1426 1427 1426 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1530 1531 1528 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1384 1561 1384 1559 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">The three SNPs showing the lowest nominal <italic>P</italic> values. Presentation of genotype distributions (%) between anxiety disorder patients and controls; &#967;<sup>2</sup> tests using the allelic model</p>
###xml 1384 1561 1384 1559 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">The three SNPs showing the lowest nominal <italic>P</italic> values. Presentation of genotype distributions (%) between anxiety disorder patients and controls; &#967;<sup>2</sup> tests using the allelic model</p></table-wrap-foot>
###xml 1064 1561 1064 1559 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="37">Association of GAT-1 single nucleotide polymorphisms with anxiety disorders</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">SNPs</th><th align="left">Patients</th><th align="left">Controls</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">rs2930152</td><td align="left">AA, 18.1; AG, 50.4; GG, 31.5</td><td align="left">AA, 13.9; AG, 43.8; GG, 48.7</td><td char="." align="char">0.0147</td></tr><tr><td align="left">rs2697153</td><td align="left">AA, 35.7; AG, 48.3; GG, 16.0</td><td align="left">AA, 46.8; AG, 40.4; GG, 12.8</td><td char="." align="char">0.0181</td></tr><tr><td align="left">rs956053</td><td align="left">CC, 54.6; CT, 41.2; TT, 4.2</td><td align="left">CC, 50.6; CT, 36.7; TT, 12.7</td><td char="." align="char">0.0263</td></tr></tbody></table><table-wrap-foot><p textid="38">The three SNPs showing the lowest nominal <italic>P</italic> values. Presentation of genotype distributions (%) between anxiety disorder patients and controls; &#967;<sup>2</sup> tests using the allelic model</p></table-wrap-foot></table-wrap>
###xml 1504 1512 <span type="species:ncbi:9606">patients</span>
In a first analysis of putative associations between anxiety disorders and genetic variability in SLC6A1, we tested for case-control differences in the distribution of alleles using a permutation-based correction (100.000 permutations) as implemented in the WG-Permer software (see Fig. 1). We found five polymorphisms of SLC6A1 to be nominally associated with the disease (P < 0.05: rs956053, rs2697153, rs2930152, rs1710879, rs2601126). Highest nominal case-control associations (P < 0.026) are listed in Table 2. Adjustment for multiple testing, however, revealed that none of them remained significantly associated (rs2930152: P = 0.202; rs2697153: P = 0.238; rs956053: P = 0.321). Fisher product combined gene-wide testing with 100.000 permutations yielded a P value of 0.03151. Despite only nominally association effects obtained for single SNPs, the results of a significant combined effect of all investigated polymorphisms as revealed by Fisher product testing strongly suggest a major role of SLC6A1 in the genetic susceptibility of pathological anxiety.Table 2Association of GAT-1 single nucleotide polymorphisms with anxiety disordersSNPsPatientsControlsP valuers2930152AA, 18.1; AG, 50.4; GG, 31.5AA, 13.9; AG, 43.8; GG, 48.70.0147rs2697153AA, 35.7; AG, 48.3; GG, 16.0AA, 46.8; AG, 40.4; GG, 12.80.0181rs956053CC, 54.6; CT, 41.2; TT, 4.2CC, 50.6; CT, 36.7; TT, 12.70.0263The three SNPs showing the lowest nominal P values. Presentation of genotype distributions (%) between anxiety disorder patients and controls; chi2 tests using the allelic model
###end p 36
###begin p 37
Association of GAT-1 single nucleotide polymorphisms with anxiety disorders
###end p 37
###begin p 38
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 146 147 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
The three SNPs showing the lowest nominal P values. Presentation of genotype distributions (%) between anxiety disorder patients and controls; chi2 tests using the allelic model
###end p 38
###begin title 39
Analysis by sequential addition of cases
###end title 39
###begin p 40
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">2006</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 961 962 959 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1025 1027 1023 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1057 1059 1055 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1163 1164 1161 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1187 1188 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1206 1208 1204 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1232 1234 1230 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1388 1389 1386 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1718 1719 1716 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1722 1729 1720 1727 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1729 1825 1727 1823 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Classification of anxiety disorder patients according to the severity of syndromal panic attacks</p>
###xml 1729 1825 1727 1823 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Classification of anxiety disorder patients according to the severity of syndromal panic attacks</p></caption>
###xml 1825 1832 1823 1830 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Subsets</th>
###xml 1832 1843 1830 1841 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PA severity</th>
###xml 1853 1854 1851 1852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1843 1855 1841 1853 <th xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="left">Patients (<italic>N</italic>)</th>
###xml 1825 1855 1823 1853 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Subsets</th><th align="left">PA severity</th><th char="." align="left">Patients (<italic>N</italic>)</th></tr>
###xml 1825 1855 1823 1853 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Subsets</th><th align="left">PA severity</th><th char="." align="left">Patients (<italic>N</italic>)</th></tr></thead>
###xml 1855 1856 1853 1854 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">I</td>
###xml 1856 1860 1854 1858 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">0&#8211;12</td>
###xml 1860 1863 1858 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">238</td>
###xml 1855 1863 1853 1861 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">I</td><td char="&#8211;" align="char">0&#8211;12</td><td char="." align="char">238</td></tr>
###xml 1863 1865 1861 1863 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">II</td>
###xml 1865 1869 1863 1867 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">3&#8211;12</td>
###xml 1869 1872 1867 1870 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">198</td>
###xml 1863 1872 1861 1870 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">II</td><td char="&#8211;" align="char">3&#8211;12</td><td char="." align="char">198</td></tr>
###xml 1872 1875 1870 1873 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">III</td>
###xml 1875 1879 1873 1877 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">6&#8211;12</td>
###xml 1879 1882 1877 1880 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">143</td>
###xml 1872 1882 1870 1880 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">III</td><td char="&#8211;" align="char">6&#8211;12</td><td char="." align="char">143</td></tr>
###xml 1882 1884 1880 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IV</td>
###xml 1884 1888 1882 1886 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">7&#8211;12</td>
###xml 1888 1890 1886 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">97</td>
###xml 1882 1890 1880 1888 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">IV</td><td char="&#8211;" align="char">7&#8211;12</td><td char="." align="char">97</td></tr>
###xml 1890 1891 1888 1889 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">V</td>
###xml 1891 1895 1889 1893 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">8&#8211;12</td>
###xml 1895 1897 1893 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">60</td>
###xml 1890 1897 1888 1895 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">V</td><td char="&#8211;" align="char">8&#8211;12</td><td char="." align="char">60</td></tr>
###xml 1897 1899 1895 1897 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">VI</td>
###xml 1899 1903 1897 1901 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">9&#8211;12</td>
###xml 1903 1905 1901 1903 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 1897 1905 1895 1903 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">VI</td><td char="&#8211;" align="char">9&#8211;12</td><td char="." align="char">33</td></tr>
###xml 1855 1905 1853 1903 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">I</td><td char="&#8211;" align="char">0&#8211;12</td><td char="." align="char">238</td></tr><tr><td align="left">II</td><td char="&#8211;" align="char">3&#8211;12</td><td char="." align="char">198</td></tr><tr><td align="left">III</td><td char="&#8211;" align="char">6&#8211;12</td><td char="." align="char">143</td></tr><tr><td align="left">IV</td><td char="&#8211;" align="char">7&#8211;12</td><td char="." align="char">97</td></tr><tr><td align="left">V</td><td char="&#8211;" align="char">8&#8211;12</td><td char="." align="char">60</td></tr><tr><td align="left">VI</td><td char="&#8211;" align="char">9&#8211;12</td><td char="." align="char">33</td></tr></tbody>
###xml 1825 1905 1823 1903 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Subsets</th><th align="left">PA severity</th><th char="." align="left">Patients (<italic>N</italic>)</th></tr></thead><tbody><tr><td align="left">I</td><td char="&#8211;" align="char">0&#8211;12</td><td char="." align="char">238</td></tr><tr><td align="left">II</td><td char="&#8211;" align="char">3&#8211;12</td><td char="." align="char">198</td></tr><tr><td align="left">III</td><td char="&#8211;" align="char">6&#8211;12</td><td char="." align="char">143</td></tr><tr><td align="left">IV</td><td char="&#8211;" align="char">7&#8211;12</td><td char="." align="char">97</td></tr><tr><td align="left">V</td><td char="&#8211;" align="char">8&#8211;12</td><td char="." align="char">60</td></tr><tr><td align="left">VI</td><td char="&#8211;" align="char">9&#8211;12</td><td char="." align="char">33</td></tr></tbody></table>
###xml 1905 2022 1903 2020 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">A severity index of 0 indicates absence of panic attacks (PA), an index of 12 the most severe form of syndromal panic</p>
###xml 1905 2022 1903 2020 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">A severity index of 0 indicates absence of panic attacks (PA), an index of 12 the most severe form of syndromal panic</p></table-wrap-foot>
###xml 1722 2022 1720 2020 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="41">Classification of anxiety disorder patients according to the severity of syndromal panic attacks</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Subsets</th><th align="left">PA severity</th><th char="." align="left">Patients (<italic>N</italic>)</th></tr></thead><tbody><tr><td align="left">I</td><td char="&#8211;" align="char">0&#8211;12</td><td char="." align="char">238</td></tr><tr><td align="left">II</td><td char="&#8211;" align="char">3&#8211;12</td><td char="." align="char">198</td></tr><tr><td align="left">III</td><td char="&#8211;" align="char">6&#8211;12</td><td char="." align="char">143</td></tr><tr><td align="left">IV</td><td char="&#8211;" align="char">7&#8211;12</td><td char="." align="char">97</td></tr><tr><td align="left">V</td><td char="&#8211;" align="char">8&#8211;12</td><td char="." align="char">60</td></tr><tr><td align="left">VI</td><td char="&#8211;" align="char">9&#8211;12</td><td char="." align="char">33</td></tr></tbody></table><table-wrap-foot><p textid="42">A severity index of 0 indicates absence of panic attacks (PA), an index of 12 the most severe form of syndromal panic</p></table-wrap-foot></table-wrap>
###xml 2022 2028 2020 2026 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 2108 2109 2106 2107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2228 2229 2226 2227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2318 2330 2316 2328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted lines</italic>
###xml 2383 2384 2381 2382 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2488 2489 2486 2487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2496 2506 2494 2504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 2522 2523 2520 2521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2531 2541 2529 2539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 2544 2551 2542 2549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">numbers</italic>
###xml 2604 2605 2602 2603 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2028 2606 2026 2604 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">Sequential analysis of patient subsets versus controls. Illustration of nominal <italic>P</italic> values for all genotyped SNPs in the genomic order as presented for the analysis of patient subset V versus controls (<bold>a</bold>). Constant increases of the odds ratio (OR) along clusters for rs2930152 and rs2697153; <italic>dotted lines</italic> assign upper and lower confidence intervals of 95% (<bold>b</bold>). Distribution of alleles (%) of rs2930152 and rs2697153 within anxiety disorder patients of subset V (<italic>n</italic> = 60; <italic>black bars</italic>) and controls (<italic>n</italic> = 267; <italic>white bars</italic>); <italic>numbers</italic> indicate the total number of alleles in each group (<bold>c</bold>)</p>
###xml 2028 2606 2026 2604 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43">Sequential analysis of patient subsets versus controls. Illustration of nominal <italic>P</italic> values for all genotyped SNPs in the genomic order as presented for the analysis of patient subset V versus controls (<bold>a</bold>). Constant increases of the odds ratio (OR) along clusters for rs2930152 and rs2697153; <italic>dotted lines</italic> assign upper and lower confidence intervals of 95% (<bold>b</bold>). Distribution of alleles (%) of rs2930152 and rs2697153 within anxiety disorder patients of subset V (<italic>n</italic> = 60; <italic>black bars</italic>) and controls (<italic>n</italic> = 267; <italic>white bars</italic>); <italic>numbers</italic> indicate the total number of alleles in each group (<bold>c</bold>)</p></caption>
###xml 2606 2606 2604 2604 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="702_2008_75_Fig2_HTML" id="MO2"/>
###xml 2022 2606 2020 2604 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="43">Sequential analysis of patient subsets versus controls. Illustration of nominal <italic>P</italic> values for all genotyped SNPs in the genomic order as presented for the analysis of patient subset V versus controls (<bold>a</bold>). Constant increases of the odds ratio (OR) along clusters for rs2930152 and rs2697153; <italic>dotted lines</italic> assign upper and lower confidence intervals of 95% (<bold>b</bold>). Distribution of alleles (%) of rs2930152 and rs2697153 within anxiety disorder patients of subset V (<italic>n</italic> = 60; <italic>black bars</italic>) and controls (<italic>n</italic> = 267; <italic>white bars</italic>); <italic>numbers</italic> indicate the total number of alleles in each group (<bold>c</bold>)</p></caption><graphic position="anchor" xlink:href="702_2008_75_Fig2_HTML" id="MO2"/></fig>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
###xml 1764 1772 <span type="species:ncbi:9606">patients</span>
###xml 2051 2058 <span type="species:ncbi:9606">patient</span>
###xml 2194 2201 <span type="species:ncbi:9606">patient</span>
###xml 2466 2474 <span type="species:ncbi:9606">patients</span>
We then re-investigated these case-control associations using the method of sequential addition of cases (ordered subset analysis) as proposed by Macgregor et al. (2006). For this purpose, we ordered patients according to the severity of syndromal panic attacks using the subscale "severity of panic attacks" of the panic and agoraphobia scale (PAS). We then created six subsets of patients (Table 3). Subset I included all study patients with valid PAS entries (scoring from 0 to 12 on this psychopathology scale). For subsets II-VI, patients with the least severity of panic attacks were removed sequentially according to the cut-off scores detailed in Table 3. In subset VI, only cases with most severe syndromal panic attacks were included. We then performed case-control associations sequentially for each subgroup. We detected the most significant associations of SLC6A1 polymorphisms when we compared patients in subset V (PAS >/= 8) with controls (Fig. 2a). The highest nominal associations were found for rs2930152 (P = 9.71e-5) and for rs2697153 (P = 0.000119) which both withstood permutation-based correction for multiple testing for all tested SNPs (n = 20) and phenotypes (n = 6) (rs2930152: P = 0.0083 and rs2697153: P = 0.0101). For these two SNPs, we observed a constant increase of the disease odds ratio (OR) with the increase in panic severity, as illustrated in Fig. 2b. While highest associations were found with subset V, we observed an even higher disease OR at both loci for subset VI (i.e., most severely affected subjects). However, the small sample size for this subgroup reduces the power to detect significant case-control associations [cf. increase of 95% confidence interval (CI); Fig. 2b).Table 3Classification of anxiety disorder patients according to the severity of syndromal panic attacksSubsetsPA severityPatients (N)I0-12238II3-12198III6-12143IV7-1297V8-1260VI9-1233A severity index of 0 indicates absence of panic attacks (PA), an index of 12 the most severe form of syndromal panicFig. 2Sequential analysis of patient subsets versus controls. Illustration of nominal P values for all genotyped SNPs in the genomic order as presented for the analysis of patient subset V versus controls (a). Constant increases of the odds ratio (OR) along clusters for rs2930152 and rs2697153; dotted lines assign upper and lower confidence intervals of 95% (b). Distribution of alleles (%) of rs2930152 and rs2697153 within anxiety disorder patients of subset V (n = 60; black bars) and controls (n = 267; white bars); numbers indicate the total number of alleles in each group (c)
###end p 40
###begin p 41
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Classification of anxiety disorder patients according to the severity of syndromal panic attacks
###end p 41
###begin p 42
A severity index of 0 indicates absence of panic attacks (PA), an index of 12 the most severe form of syndromal panic
###end p 42
###begin p 43
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 200 201 200 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 290 302 290 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted lines</italic>
###xml 355 356 355 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 468 478 468 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 503 513 503 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 516 523 516 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">numbers</italic>
###xml 576 577 576 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 23 30 <span type="species:ncbi:9606">patient</span>
###xml 166 173 <span type="species:ncbi:9606">patient</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
Sequential analysis of patient subsets versus controls. Illustration of nominal P values for all genotyped SNPs in the genomic order as presented for the analysis of patient subset V versus controls (a). Constant increases of the odds ratio (OR) along clusters for rs2930152 and rs2697153; dotted lines assign upper and lower confidence intervals of 95% (b). Distribution of alleles (%) of rs2930152 and rs2697153 within anxiety disorder patients of subset V (n = 60; black bars) and controls (n = 267; white bars); numbers indicate the total number of alleles in each group (c)
###end p 43
###begin p 44
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 70 77 <span type="species:ncbi:9606">patient</span>
###xml 480 487 <span type="species:ncbi:9606">patient</span>
###xml 611 618 <span type="species:ncbi:9606">patient</span>
The strong case-control association of rs2930152 with subset V of our patient sample is reflected by an over-representation of the G-allele in healthy controls with an OR of 2.20 (CI: 1.47-3.27), thus exerting a protective effect. Likewise, the A-allele is significantly more prevalent in controls at the rs2697153 locus (Fig. 2c). The protective effect of this allele has an OR of 2.17 (CI: 1.46-3.24). When comparing the distribution of alleles within cases and controls across patient subsets, we observed the under-representation of the G-allele at rs2930152 and of the A-allele at rs2697153 locus in every patient subset compared to controls with decreasing prevalence along increases in anxiety severity [rs2930152 G-allele frequencies: 64.2% (controls), 56.7% (subset I), 55.8% (II), 53.5% (III), 50.5% (IV), 45.0% (V), 42.4% (VI); rs2697153 A-allele frequencies: 67.0% (controls), 59.9% (subset I), 58.6% (II), 56.3% (III), 52.6% (IV), 48.3% (V), 47.0% (VI)].
###end p 44
###begin p 45
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
We further calculated a Fisher product combined gene-wide significance applying 100.000 permutations for cases of subset V versus controls and detected a P value of 0.00013, withstanding even Bonferroni correction for all performed tests (P = 0.0156). A list of all data for the genetic associations with all genotyped SNPs across the patients' subsets including the results for Fisher product combined testing is available online (Electronic supplementary material, Tables 1 and 2).
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 323 331 <span type="species:ncbi:9606">patients</span>
In our candidate gene association study we provide first evidence of a possible association of specific genetic variants within the SLC6A1 locus encoding GAT-1 with anxiety disorders with syndromal panic attacks. Furthermore, two SNPs located in the 5' region of this gene showed an increasing strength of association when patients were stratified according to the severity of panic symptoms, suggesting that our association results may be more specific for the development and severity of panic attacks than anxiety disorders per se.
###end p 47
###begin p 48
Panic attacks are circumscribed episodes of severe state anxiety lasting minutes to hours with escalating symptoms. While panic attacks are the hallmark of panic disorder, they also occur regularly in association with other anxiety disorders such as, e.g., social phobia or specific phobia.
###end p 48
###begin p 49
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 727 731 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2003</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
When we ordered patients according to the increase in panic symptom severity, the two SNPs rs2930152 and rs2697153, which are in strong LD (r2 = 1), showed a substantial increase in the strength of case-control associations. The disease OR of each SNP at different subsets displayed a constant increase reaching a value of almost 2.5 when limiting the case groups to patients with severe panic attacks (PAS > 8). This suggests that the reported finding represents an association with a specific symptom of anxiety disorders (i.e., panic attacks) rather than with a DSM-IV based diagnosis and displays a higher OR than observed in classical case-control association studies with complex psychiatric disorders (Lohmueller et al. 2003).
###end p 49
###begin p 50
###xml 647 648 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
With respect to a possible functional relevance of these SNPs we would like to note that both polymorphisms are located in the 5' flanking region of SLC6A1 with some distance (10 kb) from exon 1 of our candidate gene and putative promoter regions as predicted by the ElDorado software (data not shown; ). At this point, however, we cannot rule out that these SNPs tag another more causally related genetic variant. The LD block that contains these two SNPs stretches from exon 1 to at least 11 kb upstream of the 5' end of the gene (data according to LD mapping in our study sample), therefore including the potential 5' promoter region (see Fig. 1). This block, however, ends before the 5' neighbouring gene SLC6A11 as shown in the International HapMap Project data () suggesting that the observed association with pathological anxiety does indeed represent an association with the SLC6A1 locus.
###end p 50
###begin p 51
While awaiting replication in independent samples, our data may further highlight the major role of the GABAergic system in anxiety disorders and, especially, in the panic phenotype.
###end p 51
###begin p 52
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2006</xref>
###xml 705 709 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2001</xref>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2007</xref>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2008</xref>
###xml 888 893 888 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2004a</xref>
###xml 895 900 895 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2004b</xref>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">1999</xref>
###xml 1273 1277 1273 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">1999</xref>
###xml 1294 1298 1294 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">2002</xref>
###xml 1439 1443 1439 1443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2007</xref>
###xml 1515 1519 1515 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2005</xref>
###xml 199 204 <span type="species:ncbi:9606">human</span>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 728 735 <span type="species:ncbi:185739">Pollack</span>
###xml 1200 1204 <span type="species:ncbi:10116">rats</span>
###xml 1311 1315 <span type="species:ncbi:10090">mice</span>
###xml 1592 1596 <span type="species:ncbi:10090">mice</span>
Current clinical and preclinical studies support our evidence that genetic variants in the gene encoding GAT-1 could play an important role in the pathogenesis of pathological anxiety states. Recent human studies suggest that tiagabine, a selective blocker of GAT-1, possesses anxiolytic properties in a variety of anxiety disorders (for review see Schwartz and Nihalani 2006). Another line of evidence for an involvement of GABA transport, the main regulator of extracellular GABA, comes from magnetic resonance spectroscopy studies in anxiety disorder patients which revealed a significant reduction of GABA concentrations in several brain areas highly relevant in emotion and behaviour (Goddard et al. 2001; Ham et al. 2007; Pollack et al. 2008). It has been suggested that these reductions resemble a trait-like abnormality and might be influenced by familial factors (Goddard et al. 2004a, 2004b). Furthermore, using segregation analyses in families with affective disorders, Petty et al. (1999) report that plasma membrane GABA levels are genetically controlled, probably through autosomal recessive transmission. Using preclinical models of anxiety, the pharmacological inhibition of GAT-1 in rats has been shown to exert anxiolytic-like actions (Schmitt and Hiemke 1999; Schmitt et al. 2002). Likewise, mice deficient of the GAT-1 gene display lower levels of anxiety-like behaviours in comparison to wild-type animals (Liu et al. 2007). Using another genetic knock-out (KO) approach of GAT-1, Chiu et al. (2005) observed a large gene-dose effect on the behavioural performance of KO mice. Importantly, this finding implicates that even subtle changes in the expression or function due to genetic modifications of GAT-1 within the CNS may have a strong impact on emotional behaviours such as fear and anxiety.
###end p 52
###begin p 53
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1967</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2003</xref>
###xml 418 422 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2007</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2008</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2005</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2006</xref>
The polygenic model for the genetic susceptibility for complex diseases (Falconer 1967) suggests that several genes, all of a modest impact, contribute to the genetic susceptibility to develop or maintain complex pathologies such as anxiety disorders. So far, a multitude of positive findings linking genetic polymorphisms to anxiety disorder liability has been reported (for review, Finn et al. 2003; Gratacos et al. 2007; Hovatta and Barlow 2008), although replication in independent cohorts often failed due to phenotypic or genetic heterogeneity and methodological issues (Kendler 2005; Munafo 2006).
###end p 53
###begin p 54
###xml 23 24 23 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 378 379 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 401 402 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 744 748 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2008</xref>
###xml 1184 1191 1177 1184 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 1191 1299 1184 1292 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55">Summary of human genetic studies linking the GABA system to anxiety disorders and related personality traits</p>
###xml 1191 1299 1184 1292 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55">Summary of human genetic studies linking the GABA system to anxiety disorders and related personality traits</p></caption>
###xml 1299 1304 1292 1297 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Genes</th>
###xml 1304 1317 1297 1310 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Polymorphisms</th>
###xml 1317 1327 1310 1320 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Phenotypes</th>
###xml 1327 1335 1320 1328 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Analyses</th>
###xml 1335 1343 1328 1336 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Findings</th>
###xml 1343 1353 1336 1346 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">References</th>
###xml 1299 1353 1292 1346 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Genes</th><th align="left">Polymorphisms</th><th align="left">Phenotypes</th><th align="left">Analyses</th><th align="left">Findings</th><th align="left">References</th></tr>
###xml 1299 1353 1292 1346 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Genes</th><th align="left">Polymorphisms</th><th align="left">Phenotypes</th><th align="left">Analyses</th><th align="left">Findings</th><th align="left">References</th></tr></thead>
###xml 1353 1385 1346 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Glutamate decarboxylase 1 (GAD1)</td>
###xml 1385 1399 1378 1392 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2q31.1; 5 SNPS</td>
###xml 1399 1434 1392 1427 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GAD, PD, Agoraphobia, social phobia</td>
###xml 1434 1472 1427 1465 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case-control (589 cases, 539 patients)</td>
###xml 1472 1474 1465 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1472 1481 1465 1474 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= 0.032</td>
###xml 1497 1501 1490 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2006</xref>
###xml 1481 1502 1474 1495 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hettema et al. (<xref ref-type="bibr" rid="CR24">2006</xref>)</td>
###xml 1353 1502 1346 1495 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Glutamate decarboxylase 1 (GAD1)</td><td align="left">2q31.1; 5 SNPS</td><td align="left">GAD, PD, Agoraphobia, social phobia</td><td align="left">Case-control (589 cases, 539 patients)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Hettema et al. (<xref ref-type="bibr" rid="CR24">2006</xref>)</td></tr>
###xml 1502 1534 1495 1527 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Glutamate decarboxylase 2 (GAD2)</td>
###xml 1534 1556 1527 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10p11; dinucleotide RP</td>
###xml 1556 1594 1549 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anxiety trait (behavioural inhibition)</td>
###xml 1594 1616 1587 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Linkage (66 pedigrees)</td>
###xml 1616 1618 1609 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1616 1624 1609 1617 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= 0.05</td>
###xml 1640 1644 1633 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">2001</xref>
###xml 1624 1645 1617 1638 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Smoller et al. (<xref ref-type="bibr" rid="CR56">2001</xref>)</td>
###xml 1502 1645 1495 1638 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Glutamate decarboxylase 2 (GAD2)</td><td align="left">10p11; dinucleotide RP</td><td align="left">Anxiety trait (behavioural inhibition)</td><td align="left">Linkage (66 pedigrees)</td><td align="left"><italic>P </italic>= 0.05</td><td align="left">Smoller et al. (<xref ref-type="bibr" rid="CR56">2001</xref>)</td></tr>
###xml 1645 1651 1638 1644 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GABRA6</td>
###xml 1651 1662 1644 1655 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5q34; 1 SNP</td>
###xml 1662 1689 1655 1682 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anxiety trait (neuroticism)</td>
###xml 1689 1715 1682 1708 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dimensional (419 subjects)</td>
###xml 1715 1717 1708 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1715 1724 1708 1717 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= 0.003</td>
###xml 1736 1740 1729 1733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2004</xref>
###xml 1724 1741 1717 1734 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sen et al. (<xref ref-type="bibr" rid="CR54">2004</xref>)</td>
###xml 1645 1741 1638 1734 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">Anxiety trait (neuroticism)</td><td align="left">Dimensional (419 subjects)</td><td align="left"><italic>P </italic>= 0.003</td><td align="left">Sen et al. (<xref ref-type="bibr" rid="CR54">2004</xref>)</td></tr>
###xml 1741 1747 1734 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GABRA6</td>
###xml 1747 1758 1740 1751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5q34; 1 SNP</td>
###xml 1758 1760 1751 1753 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PD</td>
###xml 1760 1800 1753 1793 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case-control (87 patients, 114 controls)</td>
###xml 1800 1802 1793 1795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1800 1806 1793 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= NS</td>
###xml 1824 1828 1817 1821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2007</xref>
###xml 1806 1829 1799 1822 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kobayashi et al. (<xref ref-type="bibr" rid="CR32">2007</xref>)</td>
###xml 1741 1829 1734 1822 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">PD</td><td align="left">Case-control (87 patients, 114 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Kobayashi et al. (<xref ref-type="bibr" rid="CR32">2007</xref>)</td></tr>
###xml 1853 1853 1846 1846 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1829 1859 1822 1852 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GABRA1-5, GABRB1, GABRB3<break/>GABRG2</td>
###xml 1859 1902 1852 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4p14-q12, 5q32&#8211;35, 15q11&#8211;13, Xq28; (CT)n RP</td>
###xml 1902 1920 1895 1913 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PD w/o Agoraphobia</td>
###xml 1920 1942 1913 1935 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Linkage (26 pedigrees)</td>
###xml 1942 1944 1935 1937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1942 1948 1935 1941 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= NS</td>
###xml 1962 1966 1955 1959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1997</xref>
###xml 1948 1967 1941 1960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crowe et al. (<xref ref-type="bibr" rid="CR8">1997</xref>)</td>
###xml 1829 1967 1822 1960 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GABRA1-5, GABRB1, GABRB3<break/>GABRG2</td><td align="left">4p14-q12, 5q32&#8211;35, 15q11&#8211;13, Xq28; (CT)n RP</td><td align="left">PD w/o Agoraphobia</td><td align="left">Linkage (26 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Crowe et al. (<xref ref-type="bibr" rid="CR8">1997</xref>)</td></tr>
###xml 1967 1973 1960 1966 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GABRB1</td>
###xml 1973 1997 1966 1990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4p13; tetranucleotide RP</td>
###xml 1997 1999 1990 1992 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PD</td>
###xml 1999 2020 1992 2013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Linkage (5 pedigrees)</td>
###xml 2020 2022 2013 2015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2020 2026 2013 2019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= NS</td>
###xml 2041 2045 2034 2038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">1993</xref>
###xml 2026 2045 2019 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Schmidt et al. <xref ref-type="bibr" rid="CR50">1993</xref></td>
###xml 1967 2045 1960 2038 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GABRB1</td><td align="left">4p13; tetranucleotide RP</td><td align="left">PD</td><td align="left">Linkage (5 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Schmidt et al. <xref ref-type="bibr" rid="CR50">1993</xref></td></tr>
###xml 2045 2051 2038 2044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GABRB3</td>
###xml 2051 2076 2044 2069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15q11-13; dinucleotide RP</td>
###xml 2076 2080 2069 2073 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PTSD</td>
###xml 2080 2104 2073 2097 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dimensional (86 subjets)</td>
###xml 2104 2106 2097 2099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2104 2114 2097 2107 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= 0.0002</td>
###xml 2130 2134 2123 2127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2001</xref>
###xml 2114 2135 2107 2128 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Feusner et al. (<xref ref-type="bibr" rid="CR12">2001</xref>)</td>
###xml 2045 2135 2038 2128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GABRB3</td><td align="left">15q11-13; dinucleotide RP</td><td align="left">PTSD</td><td align="left">Dimensional (86 subjets)</td><td align="left"><italic>P </italic>= 0.0002</td><td align="left">Feusner et al. (<xref ref-type="bibr" rid="CR12">2001</xref>)</td></tr>
###xml 2135 2141 2128 2134 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GABBR1</td>
###xml 2141 2153 2134 2146 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4p13; 3 SNPs</td>
###xml 2153 2155 2146 2148 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PD</td>
###xml 2155 2194 2148 2187 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case&#8211;control (87 patients, 89 controls)</td>
###xml 2194 2196 2187 2189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2194 2200 2187 2193 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= NS</td>
###xml 2213 2217 2206 2210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2000</xref>
###xml 2200 2218 2193 2211 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sand et al. (<xref ref-type="bibr" rid="CR48">2000</xref>)</td>
###xml 2135 2218 2128 2211 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GABBR1</td><td align="left">4p13; 3 SNPs</td><td align="left">PD</td><td align="left">Case&#8211;control (87 patients, 89 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Sand et al. (<xref ref-type="bibr" rid="CR48">2000</xref>)</td></tr>
###xml 2218 2250 2211 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diazepam binding inhibitor (DBI)</td>
###xml 2250 2263 2243 2256 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2p14.2; 1 SNP</td>
###xml 2263 2288 2256 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anxiety disorders with PA</td>
###xml 2288 2329 2281 2322 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case&#8211;control (176 patients, 301 controls)</td>
###xml 2329 2331 2322 2324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 2329 2338 2322 2331 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P </italic>= 0.032</td>
###xml 2357 2361 2350 2354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">2007</xref>
###xml 2338 2362 2331 2355 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Thoeringer et al. (<xref ref-type="bibr" rid="CR57">2007</xref>)</td>
###xml 2218 2362 2211 2355 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Diazepam binding inhibitor (DBI)</td><td align="left">2p14.2; 1 SNP</td><td align="left">Anxiety disorders with PA</td><td align="left">Case&#8211;control (176 patients, 301 controls)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Thoeringer et al. (<xref ref-type="bibr" rid="CR57">2007</xref>)</td></tr>
###xml 1353 2362 1346 2355 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Glutamate decarboxylase 1 (GAD1)</td><td align="left">2q31.1; 5 SNPS</td><td align="left">GAD, PD, Agoraphobia, social phobia</td><td align="left">Case-control (589 cases, 539 patients)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Hettema et al. (<xref ref-type="bibr" rid="CR24">2006</xref>)</td></tr><tr><td align="left">Glutamate decarboxylase 2 (GAD2)</td><td align="left">10p11; dinucleotide RP</td><td align="left">Anxiety trait (behavioural inhibition)</td><td align="left">Linkage (66 pedigrees)</td><td align="left"><italic>P </italic>= 0.05</td><td align="left">Smoller et al. (<xref ref-type="bibr" rid="CR56">2001</xref>)</td></tr><tr><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">Anxiety trait (neuroticism)</td><td align="left">Dimensional (419 subjects)</td><td align="left"><italic>P </italic>= 0.003</td><td align="left">Sen et al. (<xref ref-type="bibr" rid="CR54">2004</xref>)</td></tr><tr><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">PD</td><td align="left">Case-control (87 patients, 114 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Kobayashi et al. (<xref ref-type="bibr" rid="CR32">2007</xref>)</td></tr><tr><td align="left">GABRA1-5, GABRB1, GABRB3<break/>GABRG2</td><td align="left">4p14-q12, 5q32&#8211;35, 15q11&#8211;13, Xq28; (CT)n RP</td><td align="left">PD w/o Agoraphobia</td><td align="left">Linkage (26 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Crowe et al. (<xref ref-type="bibr" rid="CR8">1997</xref>)</td></tr><tr><td align="left">GABRB1</td><td align="left">4p13; tetranucleotide RP</td><td align="left">PD</td><td align="left">Linkage (5 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Schmidt et al. <xref ref-type="bibr" rid="CR50">1993</xref></td></tr><tr><td align="left">GABRB3</td><td align="left">15q11-13; dinucleotide RP</td><td align="left">PTSD</td><td align="left">Dimensional (86 subjets)</td><td align="left"><italic>P </italic>= 0.0002</td><td align="left">Feusner et al. (<xref ref-type="bibr" rid="CR12">2001</xref>)</td></tr><tr><td align="left">GABBR1</td><td align="left">4p13; 3 SNPs</td><td align="left">PD</td><td align="left">Case&#8211;control (87 patients, 89 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Sand et al. (<xref ref-type="bibr" rid="CR48">2000</xref>)</td></tr><tr><td align="left">Diazepam binding inhibitor (DBI)</td><td align="left">2p14.2; 1 SNP</td><td align="left">Anxiety disorders with PA</td><td align="left">Case&#8211;control (176 patients, 301 controls)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Thoeringer et al. (<xref ref-type="bibr" rid="CR57">2007</xref>)</td></tr></tbody>
###xml 1299 2362 1292 2355 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Genes</th><th align="left">Polymorphisms</th><th align="left">Phenotypes</th><th align="left">Analyses</th><th align="left">Findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Glutamate decarboxylase 1 (GAD1)</td><td align="left">2q31.1; 5 SNPS</td><td align="left">GAD, PD, Agoraphobia, social phobia</td><td align="left">Case-control (589 cases, 539 patients)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Hettema et al. (<xref ref-type="bibr" rid="CR24">2006</xref>)</td></tr><tr><td align="left">Glutamate decarboxylase 2 (GAD2)</td><td align="left">10p11; dinucleotide RP</td><td align="left">Anxiety trait (behavioural inhibition)</td><td align="left">Linkage (66 pedigrees)</td><td align="left"><italic>P </italic>= 0.05</td><td align="left">Smoller et al. (<xref ref-type="bibr" rid="CR56">2001</xref>)</td></tr><tr><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">Anxiety trait (neuroticism)</td><td align="left">Dimensional (419 subjects)</td><td align="left"><italic>P </italic>= 0.003</td><td align="left">Sen et al. (<xref ref-type="bibr" rid="CR54">2004</xref>)</td></tr><tr><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">PD</td><td align="left">Case-control (87 patients, 114 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Kobayashi et al. (<xref ref-type="bibr" rid="CR32">2007</xref>)</td></tr><tr><td align="left">GABRA1-5, GABRB1, GABRB3<break/>GABRG2</td><td align="left">4p14-q12, 5q32&#8211;35, 15q11&#8211;13, Xq28; (CT)n RP</td><td align="left">PD w/o Agoraphobia</td><td align="left">Linkage (26 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Crowe et al. (<xref ref-type="bibr" rid="CR8">1997</xref>)</td></tr><tr><td align="left">GABRB1</td><td align="left">4p13; tetranucleotide RP</td><td align="left">PD</td><td align="left">Linkage (5 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Schmidt et al. <xref ref-type="bibr" rid="CR50">1993</xref></td></tr><tr><td align="left">GABRB3</td><td align="left">15q11-13; dinucleotide RP</td><td align="left">PTSD</td><td align="left">Dimensional (86 subjets)</td><td align="left"><italic>P </italic>= 0.0002</td><td align="left">Feusner et al. (<xref ref-type="bibr" rid="CR12">2001</xref>)</td></tr><tr><td align="left">GABBR1</td><td align="left">4p13; 3 SNPs</td><td align="left">PD</td><td align="left">Case&#8211;control (87 patients, 89 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Sand et al. (<xref ref-type="bibr" rid="CR48">2000</xref>)</td></tr><tr><td align="left">Diazepam binding inhibitor (DBI)</td><td align="left">2p14.2; 1 SNP</td><td align="left">Anxiety disorders with PA</td><td align="left">Case&#8211;control (176 patients, 301 controls)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Thoeringer et al. (<xref ref-type="bibr" rid="CR57">2007</xref>)</td></tr></tbody></table>
###xml 2362 2367 2355 2360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABRA</italic>
###xml 2423 2429 2412 2418 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GABRB</italic>
###xml 2484 2490 2469 2475 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GABRG</italic>
###xml 2546 2552 2527 2533 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GABBR</italic>
###xml 2674 2678 2655 2659 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GAD</italic>
###xml 2709 2711 2690 2692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 2729 2731 2710 2712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP</italic>
###xml 2754 2756 2735 2737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD</italic>
###xml 2773 2775 2754 2756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PA</italic>
###xml 2791 2795 2772 2776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTSD</italic>
###xml 2827 2830 2808 2811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNP</italic>
###xml 2362 2861 2355 2842 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="56"><italic>GABRA</italic> &#947;-aminobutyric acid receptor type A, alpha subunit;<italic> GABRB</italic> &#947;-aminobutyric acid receptor type A, beta subunit;<italic> GABRG</italic> &#947;-aminobutyric acid receptor type A, gamma subunit;<italic> GABBR</italic> aminobutyric acid receptor type B (for further details on gene names and symbols see HUGO Gene Nomenclature Committee, <ext-link ext-link-type="uri" xlink:href="http://www.genenames.org">www.genenames.org</ext-link>),<italic> GAD</italic> generalized anxiety disorder, <italic>NS</italic> not significant, <italic>RP</italic> repeat polymorphisms, <italic>PD</italic> panic disorder, <italic>PA</italic> panic attacks, <italic>PTSD</italic> posttraumatic stress disorder, <italic>SNP</italic> single nucleotide polymorphism</p>
###xml 2362 2861 2355 2842 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="56"><italic>GABRA</italic> &#947;-aminobutyric acid receptor type A, alpha subunit;<italic> GABRB</italic> &#947;-aminobutyric acid receptor type A, beta subunit;<italic> GABRG</italic> &#947;-aminobutyric acid receptor type A, gamma subunit;<italic> GABBR</italic> aminobutyric acid receptor type B (for further details on gene names and symbols see HUGO Gene Nomenclature Committee, <ext-link ext-link-type="uri" xlink:href="http://www.genenames.org">www.genenames.org</ext-link>),<italic> GAD</italic> generalized anxiety disorder, <italic>NS</italic> not significant, <italic>RP</italic> repeat polymorphisms, <italic>PD</italic> panic disorder, <italic>PA</italic> panic attacks, <italic>PTSD</italic> posttraumatic stress disorder, <italic>SNP</italic> single nucleotide polymorphism</p></table-wrap-foot>
###xml 1184 2861 1177 2842 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="55">Summary of human genetic studies linking the GABA system to anxiety disorders and related personality traits</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Genes</th><th align="left">Polymorphisms</th><th align="left">Phenotypes</th><th align="left">Analyses</th><th align="left">Findings</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Glutamate decarboxylase 1 (GAD1)</td><td align="left">2q31.1; 5 SNPS</td><td align="left">GAD, PD, Agoraphobia, social phobia</td><td align="left">Case-control (589 cases, 539 patients)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Hettema et al. (<xref ref-type="bibr" rid="CR24">2006</xref>)</td></tr><tr><td align="left">Glutamate decarboxylase 2 (GAD2)</td><td align="left">10p11; dinucleotide RP</td><td align="left">Anxiety trait (behavioural inhibition)</td><td align="left">Linkage (66 pedigrees)</td><td align="left"><italic>P </italic>= 0.05</td><td align="left">Smoller et al. (<xref ref-type="bibr" rid="CR56">2001</xref>)</td></tr><tr><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">Anxiety trait (neuroticism)</td><td align="left">Dimensional (419 subjects)</td><td align="left"><italic>P </italic>= 0.003</td><td align="left">Sen et al. (<xref ref-type="bibr" rid="CR54">2004</xref>)</td></tr><tr><td align="left">GABRA6</td><td align="left">5q34; 1 SNP</td><td align="left">PD</td><td align="left">Case-control (87 patients, 114 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Kobayashi et al. (<xref ref-type="bibr" rid="CR32">2007</xref>)</td></tr><tr><td align="left">GABRA1-5, GABRB1, GABRB3<break/>GABRG2</td><td align="left">4p14-q12, 5q32&#8211;35, 15q11&#8211;13, Xq28; (CT)n RP</td><td align="left">PD w/o Agoraphobia</td><td align="left">Linkage (26 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Crowe et al. (<xref ref-type="bibr" rid="CR8">1997</xref>)</td></tr><tr><td align="left">GABRB1</td><td align="left">4p13; tetranucleotide RP</td><td align="left">PD</td><td align="left">Linkage (5 pedigrees)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Schmidt et al. <xref ref-type="bibr" rid="CR50">1993</xref></td></tr><tr><td align="left">GABRB3</td><td align="left">15q11-13; dinucleotide RP</td><td align="left">PTSD</td><td align="left">Dimensional (86 subjets)</td><td align="left"><italic>P </italic>= 0.0002</td><td align="left">Feusner et al. (<xref ref-type="bibr" rid="CR12">2001</xref>)</td></tr><tr><td align="left">GABBR1</td><td align="left">4p13; 3 SNPs</td><td align="left">PD</td><td align="left">Case&#8211;control (87 patients, 89 controls)</td><td align="left"><italic>P </italic>= NS</td><td align="left">Sand et al. (<xref ref-type="bibr" rid="CR48">2000</xref>)</td></tr><tr><td align="left">Diazepam binding inhibitor (DBI)</td><td align="left">2p14.2; 1 SNP</td><td align="left">Anxiety disorders with PA</td><td align="left">Case&#8211;control (176 patients, 301 controls)</td><td align="left"><italic>P </italic>= 0.032</td><td align="left">Thoeringer et al. (<xref ref-type="bibr" rid="CR57">2007</xref>)</td></tr></tbody></table><table-wrap-foot><p textid="56"><italic>GABRA</italic> &#947;-aminobutyric acid receptor type A, alpha subunit;<italic> GABRB</italic> &#947;-aminobutyric acid receptor type A, beta subunit;<italic> GABRG</italic> &#947;-aminobutyric acid receptor type A, gamma subunit;<italic> GABBR</italic> aminobutyric acid receptor type B (for further details on gene names and symbols see HUGO Gene Nomenclature Committee, <ext-link ext-link-type="uri" xlink:href="http://www.genenames.org">www.genenames.org</ext-link>),<italic> GAD</italic> generalized anxiety disorder, <italic>NS</italic> not significant, <italic>RP</italic> repeat polymorphisms, <italic>PD</italic> panic disorder, <italic>PA</italic> panic attacks, <italic>PTSD</italic> posttraumatic stress disorder, <italic>SNP</italic> single nucleotide polymorphism</p></table-wrap-foot></table-wrap>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 1042 1048 <span type="species:ncbi:9606">person</span>
###xml 1202 1207 <span type="species:ncbi:9606">human</span>
###xml 1463 1471 <span type="species:ncbi:9606">patients</span>
###xml 1777 1785 <span type="species:ncbi:9606">patients</span>
###xml 2172 2180 <span type="species:ncbi:9606">patients</span>
###xml 2306 2314 <span type="species:ncbi:9606">patients</span>
As summarized in Table 4, several human genetic linkage and association studies have investigated the genetic load of GABA system pathways on the psychobiology of anxiety. Positive signals for an association with anxiety disorders and anxiety-related personality traits have been observed for genes encoding glutamic acid decarboxylase, the alpha6 and beta3 subunits of the GABAA receptor, type 1 GABAB receptor and the diazepam binding inhibitor. These published observations, together with our findings, may implicate a multiple system hit-theory in the genetic underpinning of anxiety disorder as it was recently described for the lithium-sensitive phoshatidylinositol pathway in the genetic susceptibility for bipolar disorder (Baum et al. 2008). Thus, no single genetic polymorphism or a small set of SNPs within a component of this neuroinhibitory pathway is sufficient to trigger the disease. However, many loci at different genes of the GABA system, each of a small effect size, may contribute to an individual's disease risk. If the person's total burden of risk loci reaches some threshold, pathological anxiety could develop under the influence of adverse exogenic factors.Table 4Summary of human genetic studies linking the GABA system to anxiety disorders and related personality traitsGenesPolymorphismsPhenotypesAnalysesFindingsReferencesGlutamate decarboxylase 1 (GAD1)2q31.1; 5 SNPSGAD, PD, Agoraphobia, social phobiaCase-control (589 cases, 539 patients)P = 0.032Hettema et al. (2006)Glutamate decarboxylase 2 (GAD2)10p11; dinucleotide RPAnxiety trait (behavioural inhibition)Linkage (66 pedigrees)P = 0.05Smoller et al. (2001)GABRA65q34; 1 SNPAnxiety trait (neuroticism)Dimensional (419 subjects)P = 0.003Sen et al. (2004)GABRA65q34; 1 SNPPDCase-control (87 patients, 114 controls)P = NSKobayashi et al. (2007)GABRA1-5, GABRB1, GABRB3GABRG24p14-q12, 5q32-35, 15q11-13, Xq28; (CT)n RPPD w/o AgoraphobiaLinkage (26 pedigrees)P = NSCrowe et al. (1997)GABRB14p13; tetranucleotide RPPDLinkage (5 pedigrees)P = NSSchmidt et al. 1993GABRB315q11-13; dinucleotide RPPTSDDimensional (86 subjets)P = 0.0002Feusner et al. (2001)GABBR14p13; 3 SNPsPDCase-control (87 patients, 89 controls)P = NSSand et al. (2000)Diazepam binding inhibitor (DBI)2p14.2; 1 SNPAnxiety disorders with PACase-control (176 patients, 301 controls)P = 0.032Thoeringer et al. (2007)GABRA gamma-aminobutyric acid receptor type A, alpha subunit; GABRB gamma-aminobutyric acid receptor type A, beta subunit; GABRG gamma-aminobutyric acid receptor type A, gamma subunit; GABBR aminobutyric acid receptor type B (for further details on gene names and symbols see HUGO Gene Nomenclature Committee, ), GAD generalized anxiety disorder, NS not significant, RP repeat polymorphisms, PD panic disorder, PA panic attacks, PTSD posttraumatic stress disorder, SNP single nucleotide polymorphism
###end p 54
###begin p 55
###xml 11 16 <span type="species:ncbi:9606">human</span>
Summary of human genetic studies linking the GABA system to anxiety disorders and related personality traits
###end p 55
###begin p 56
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GABRA</italic>
###xml 61 67 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GABRB</italic>
###xml 122 128 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GABRG</italic>
###xml 184 190 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GABBR</italic>
###xml 312 316 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> GAD</italic>
###xml 347 349 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 367 369 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP</italic>
###xml 392 394 380 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD</italic>
###xml 411 413 399 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PA</italic>
###xml 429 433 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTSD</italic>
###xml 465 468 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNP</italic>
GABRA gamma-aminobutyric acid receptor type A, alpha subunit; GABRB gamma-aminobutyric acid receptor type A, beta subunit; GABRG gamma-aminobutyric acid receptor type A, gamma subunit; GABBR aminobutyric acid receptor type B (for further details on gene names and symbols see HUGO Gene Nomenclature Committee, ), GAD generalized anxiety disorder, NS not significant, RP repeat polymorphisms, PD panic disorder, PA panic attacks, PTSD posttraumatic stress disorder, SNP single nucleotide polymorphism
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 201 209 <span type="species:ncbi:9606">patients</span>
In essence, our results indicate that genetic variance in SLC6A1 may be associated with the aetiopathogenesis of anxiety disorders and, importantly, may modulate the severity of panic attacks in these patients. Although this study lacks independent confirmation and further data about the neurobiological relevance of our findings, it supports the involvement of a dysregulation in GABAergic circuits in pathological anxiety and highlights GAT-1 as a promising target for the treatment of anxiety disorders and specifically for panic symptoms. First positive clinical studies with GAT-1 inhibitors substantiate this idea.
###end p 58
###begin title 59
Electronic supplementary material
###end title 59
###begin p 60
Below is the link to the electronic supplementary material.
###end p 60
###begin p 61
MOESM1 [INSERT CAPTION HERE] (DOC 292 kb)
###end p 61
###begin p 62
The authors would like to thank Stefan Kloiber, Sonja Horstmann, Hubertus Himmerich, Martin Kohli, Daria Salyakina, Angela Heck, Andrea Ellgas, Hildegard Pfister and Roselind Lieb for their valuable help in performing the studies, Maria Asmus, Sabine Damast, Maik Koedel, Angelika Sangl, Susann Sauer and Alina Tontsch for expert technical assistance. This work has been funded by the Bavarian Ministry of Commerce and by the Federal Ministry of Education and Research (BMBF) within the framework of the National Genome Research Network (NGFN), Forderkennzeichen 01GS0481. The authors are responsible for the contents of this publication.
###end p 62
###begin p 63
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 63
###begin title 64
References
###end title 64
###begin article-title 65
Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
###end article-title 65
###begin article-title 66
Assessing the efficacy of treatments for panic disorder and agoraphobia, II: the Panic and Agoraphobia Scale
###end article-title 66
###begin article-title 67
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder
###end article-title 67
###begin article-title 68
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment
###end article-title 68
###begin article-title 69
Open-label tiagabine monotherapy for major depressive disorder with anxiety
###end article-title 69
###begin article-title 70
GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum
###end article-title 70
###begin article-title 71
Tiagabine for post-traumatic stress disorder: effect of open-label and double-blind discontinuation treatment
###end article-title 71
###begin article-title 72
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
Candidate gene study of eight GABAA receptor subunits in panic disorder
###end article-title 72
###begin article-title 73
Inhibition of gamma-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures
###end article-title 73
###begin article-title 74
Genomic control for association studies
###end article-title 74
###begin article-title 75
The inheritance of liability to diseases with variable age of onset, with particular reference to diabetes mellitus
###end article-title 75
###begin article-title 76
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
GABAA receptor beta3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population
###end article-title 76
###begin article-title 77
Genetic animal models of anxiety
###end article-title 77
###begin article-title 78
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 78
###begin article-title 79
Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy
###end article-title 79
###begin article-title 80
Family psychopathology and magnitude of reductions in occipital cortex GABA levels in panic disorder
###end article-title 80
###begin article-title 81
Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder
###end article-title 81
###begin article-title 82
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
Candidate genes for panic disorder: insights form human and mouse genetic studies
###end article-title 82
###begin article-title 83
Decreased GABA levels in anterior cingulated and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study
###end article-title 83
###begin article-title 84
The assessment of anxiety-states by rating
###end article-title 84
###begin article-title 85
A rating scale for depression
###end article-title 85
###begin article-title 86
###xml 81 84 <span type="species:ncbi:9606">men</span>
###xml 89 94 <span type="species:ncbi:9606">women</span>
The structure of genetic and environmental risk factors for anxiety disorders in men and women
###end article-title 86
###begin article-title 87
Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism
###end article-title 87
###begin article-title 88
Is the comorbidity between social phobia and panic disorder due to familial cotransmission or other factors?
###end article-title 88
###begin article-title 89
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 42 45 <span type="species:ncbi:9606">men</span>
Molecular genetics of anxiety in mice and men
###end article-title 89
###begin article-title 90
Role of GABA in memory and anxiety
###end article-title 90
###begin article-title 91
Role of GABA in anxiety and depression
###end article-title 91
###begin article-title 92
Psychiatric genetics: a methodologic critique
###end article-title 92
###begin article-title 93
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication
###end article-title 93
###begin article-title 94
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication
###end article-title 94
###begin article-title 95
Lack of polymorphism in genes encoding mGluR7, mGluR8, GABA(A) receptor alfa-6 subunit and nociceptin/orphanin FQ receptor and panic disorder
###end article-title 95
###begin article-title 96
The new antiepileptic drugs
###end article-title 96
###begin article-title 97
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Reduced anxiety and depression-like behaviours in mice lacking GABA transporter subtype 1
###end article-title 97
###begin article-title 98
Meta-analysis of genetic association studies support a contribution of common variants to susceptibility to common disease
###end article-title 98
###begin article-title 99
Specificity of familial transmission of anxiety and comorbid disorders
###end article-title 99
###begin article-title 100
Use of phenotypic covariates in association analysis by sequential addition of cases
###end article-title 100
###begin article-title 101
Depression, anxiety, and the gastrointestinal system
###end article-title 101
###begin article-title 102
Longitudinal trajectories of depression and anxiety in a prospective community study
###end article-title 102
###begin article-title 103
Candidate gene studies in the 21st century: meta-analysis, mediation, moderation
###end article-title 103
###begin article-title 104
The role of GABA in the pathophysiology and treatment of anxiety disorders
###end article-title 104
###begin article-title 105
Differential familial liability of panic disorder and agoraphobia
###end article-title 105
###begin article-title 106
###xml 49 54 <span type="species:ncbi:9606">human</span>
Evidence for the segregation of a major gene for human plasma GABA levels
###end article-title 106
###begin article-title 107
The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study
###end article-title 107
###begin article-title 108
High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam
###end article-title 108
###begin article-title 109
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions
###end article-title 109
###begin article-title 110
Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control
###end article-title 110
###begin article-title 111
Exonic variants of the GABA(B) receptor gene and panic disorder
###end article-title 111
###begin article-title 112
GABA transporters and GABA-transaminase as drug targets
###end article-title 112
###begin article-title 113
Excluding linkage between panic disorder and the gamma-aminobutyric acid beta 1 receptor locus in five Icelandic pedigrees
###end article-title 113
###begin article-title 114
###xml 48 51 <span type="species:ncbi:10116">rat</span>
Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze
###end article-title 114
###begin article-title 115
###xml 76 80 <span type="species:ncbi:10116">rats</span>
Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats
###end article-title 115
###begin article-title 116
Tiagabine in anxiety disorders
###end article-title 116
###begin article-title 117
Serotonin transporter and GABA(A) alpha 6 receptor variants are associated with neuroticism
###end article-title 117
###begin article-title 118
An open-label study of tiagabine in panic disorder
###end article-title 118
###begin article-title 119
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Genetic association analysis of behavioral inhibition using candidate loci from mouse models
###end article-title 119
###begin article-title 120
Association with a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety disorders with panic attacks
###end article-title 120
###begin article-title 121
Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review
###end article-title 121
###begin article-title 122
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder
###end article-title 122
###begin article-title 123
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Tiagabine improves panic and agoraphobia in panic disorder patients
###end article-title 123
###begin p 124
C. K. Thoeringer and S. Ripke contributed equally to this work.
###end p 124
###begin p 125
Dedicated to the Special Issue "Fear, Anxiety and Anxiety Disorder".
###end p 125
###begin p 126
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 126
###begin p 127
The online version of this article (doi:10.1007/s00702-008-0075-y) contains supplementary material, which is available to authorized users.
###end p 127

